# BetaGlue Therapeutics S.p.A.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/betaglue-therapeutics-s-p-a

- Industry: Medical Devices & Equipment
- Headquarters: Milan, Italy
- Website: www.betaglue.com
- Total disclosed funding: $4.7M
- Latest round: Series A (Sep 7, 2016)
- Investors on record: 2

## About

Based in Milan, Italy, and founded in 2017, BetaGlue Therapeutics S.p.A. operates as a clinical-stage oncology company that focuses on developing radiotherapeutic treatments for cancer. In December 2024, BetaGlue Therapeutics S.p.A. raised EUR 6 million in venture funding from new investor ENEA Tech e Biomedical Foundation. The company’s flagship product, YntraDose, represents a groundbreaking advancement in interventional oncology, offering a targeted and personalized approach to radiotherapy. BetaGlue Therapeutics addresses the limitations of existing radiotherapy methods, such as stereotactic body radiotherapy (SBRT) and proton beam radiotherapy (PBRT), which often struggle with challenges like internal organ movement and require significant investment in specialized equipment. The company will use the December 2024 funding to support its research and development in the field of life sciences.

## Funding rounds

- Series A, Sep 7, 2016, $4.7M — Innogest, Panakes Partners

## Investors

- Innogest (https://capitalatlas.ai/funds/innogest) — Series A
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series A